BALTIMORE, MD--(Marketwired - May 29, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, has initiated research coverage of Plandai Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

Leveraging its highly bioavailable plant extracts and its proprietary extraction processes, Plandai is poised to transform how many diseases and conditions are treated, including malaria, cardiovascular health, weight management, etc. According to published USDA studies, the Plandai product has demonstrated to have improved bioavailability over other products far exceeding anything currently available today. This means that the rate to which an active ingredient can be absorbed by the body's tissues is very high.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.

"Based on recent test results, Plandai has made great strides toward treating and preventing malaria, which in 2010 caused an estimated 216 million clinical episodes, 655,000 deaths and had an estimated $12 billion in direct treatment costs. Given the potentially low-cost and highly efficacious malaria treatment under development, Plandai's Phytofare™ Catechin Extract could become a de facto standard in Africa, which accounted for 91% of all malaria-related deaths. Plus, due to the Company's highly bioavailable plant extracts, Plandai could enjoy strong sales across the globe in the nutraceutical industry as a means to improve health and wellness. In order to generate an equivalent health benefit to Phytofare™, consumers would have to purchase and consume anywhere from 6-8 times as much of competing products."

To view a summary of the report or download the report in its entirety, please visit
www.goldmanresearch.com

Additional detail via the Goldman Small Cap Research article as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.